Top Industry Leaders in the Ankylosing Spondylitis Treatment Market
Latest Ankylosing Spondylitis Treatment Companies Update:
Lynk Therapeutics Announces Positive Phase 2b Results for LNK01001: This October 2023 news reported significant efficacy and favorable safety profile for LNK01001, a novel JAK1 selective inhibitor, in treating AS patients. Phase 3 trials are expected to begin soon.
Novartis Launches Phase 3 Trial for Cosentyx in Non-radiographic Axial Spondyloarthritis: This November 2023 development expands the potential reach of Cosentyx, a biologic already approved for AS, to patients with non-radiographic forms of the disease.
AbbVie Initiates Phase 2 Trial for Upadacitinib in Ankylosing Spondylitis: This January 2024 announcement strengthens AbbVie's presence in the AS market with a potential new JAK inhibitor option.
FDA Approves Intravenous Cosentyx for Ankylosing Spondylitis: This June 2023 approval offers a new administration option for Cosentyx, potentially improving convenience and compliance for some patients.
Expansion of Biosimilar Options for Existing Drugs: Increased availability of biosimilars for TNF-alpha inhibitors like Remicade and Humira could increase treatment access and potentially reduce costs.
List of Ankylosing Spondylitis Treatment Key companies in the market
- AbbVie Inc.
- Janssen Pharmaceuticals Inc.
- Pfizer Inc.
- Sandoz International GmbH
- Amgen Inc.
- Protalix BioTherapeutics, Inc.
- Reliance Life Sciences Pvt. Ltd.
- Momenta Pharmaceuticals Inc.
- Celgene Corporation
- Regeneron Pharmaceuticals
- Merck & Co. Inc